1-3 of 3
Viola Festuccia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Response to Imatinib or Imatinib Containing Regimens of Secondary Clones in Chronic Myeloid Leukemia Patients with Additional Chromosomal Abnormalities.

Debora Luzi, M.D., Lorenzo Falchi, M.D., Giovanna Rege Cambrin, M.D., Emilia Giugliano, Ph.D., Monica Schippa, M.D., Viola Festuccia, M.D., Ilaria Angeletti, M.D., Emilio Donti, M.D., Anna Marina Liberati, MD
Journal: Blood
Blood (2007) 110 (11): 4574.
https://doi.org/10.1182/blood.V110.11.4574.4574
Published: 2007
Journal Articles

Impact of Complete Kariotypic Remission (CKR) and Sokal Risk on Overall Survival in Chronic Myelogenous Leukemia (CML) Patients: A Monocentric Experience.

Lorenzo Falchi, Monica Schippa, Debora Luzi, Rita Emili, Viola Festuccia, Emilia Giugliano, Carmela Ardisia, Annamaria Rauco, Roberta Pace, Emilio Donti, Anna Marina Liberati
Journal: Blood
Blood (2006) 108 (11): 4803.
https://doi.org/10.1182/blood.V108.11.4803.4803
Published: 2006
Journal Articles

Philadelphia Chromosome (Ph’) Secondary Clones in Chronic Myeloid Leukemia (CML) Are Not Indicative of Resistance to IFNa- or Imatinib-Based Treatment Regimens.

Lorenzo Falchi, Paolo Prontera, Debora Luzi, Viola Festuccia, Rita Emili, Enrico Gottardi, Emilio Donti, Anna Marina Liberati
Journal: Blood
Blood (2006) 108 (11): 4806.
https://doi.org/10.1182/blood.V108.11.4806.4806
Published: 2006